160 related articles for article (PubMed ID: 38201618)
1. Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions.
Sodji QH; Forsberg MH; Cappabianca D; Kerr CP; Sarko L; Shea A; Adam DP; Eickhoff JC; Ong IM; Hernandez R; Weichert J; Bednarz BP; Saha K; Sondel PM; Capitini CM; Morris ZS
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201618
[TBL] [Abstract][Full Text] [Related]
2. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
[TBL] [Abstract][Full Text] [Related]
3. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
4. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
5. Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.
Yang Y; Vedvyas Y; Alcaina Y; Son JY; Min IM; Jin MM
Front Immunol; 2024; 15():1355388. PubMed ID: 38550578
[TBL] [Abstract][Full Text] [Related]
6. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
8. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
9. A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy.
Adhikarla V; Awuah D; Brummer AB; Caserta E; Krishnan A; Pichiorri F; Minnix M; Shively JE; Wong JYC; Wang X; Rockne RC
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680320
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
12. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y
Cytotherapy; 2024 May; ():. PubMed ID: 38904586
[TBL] [Abstract][Full Text] [Related]
14. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of
Luna-Gutiérrez M; Cruz-Nova P; Jiménez-Mancilla N; Oros-Pantoja R; Lara-Almazán N; Santos-Cuevas C; Azorín-Vega E; Ocampo-García B; Ferro-Flores G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569758
[TBL] [Abstract][Full Text] [Related]
16. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies.
Zhang J; Webster S; Duffin B; Bernstein MN; Steill J; Swanson S; Forsberg MH; Bolin J; Brown ME; Majumder A; Capitini CM; Stewart R; Thomson JA; Slukvin II
Stem Cell Reports; 2023 Feb; 18(2):585-596. PubMed ID: 36638788
[TBL] [Abstract][Full Text] [Related]
17. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P; Di Carlo E; Caruana I; Emionite L; Cilli M; De Angelis B; Quintarelli C; Pezzolo A; Raffaghello L; Morandi F; Locatelli F; Pistoia V; Prigione I
Oncoimmunology; 2017; 7(1):e1378843. PubMed ID: 29296542
[TBL] [Abstract][Full Text] [Related]
19. GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.
Chulanetra M; Morchang A; Sayour E; Eldjerou L; Milner R; Lagmay J; Cascio M; Stover B; Slayton W; Chaicumpa W; Yenchitsomanus PT; Chang LJ
Am J Cancer Res; 2020; 10(2):674-687. PubMed ID: 32195035
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]